| 证券代码 | INSY.O |
| 证券名称 | Insys Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2013-05-02 |
| 首发价格(元) | 8 USD |
| 首发数量(股) | 4000000 |
| 首发募资额(元) | 32,000,000.00 USD |
| 首发主承销商 | JMP Securities LLC,Wells Fargo Securities, LLC |
| 货币单位 | USD |
| 公司名称 | Insys Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 1333 S. Spectrum Blvd, Suite 100, Chandler, Arizona, USA |
| 成立日期 | 1990-06 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.insysrx.com |
| 电话 | +1 (480) 500-3127 |
| 传真 | - |
| 公司简介 | Insys Therapeutics, Inc. is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need. SUBSYS and SYNDRO are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc. |